ProSense® Shines at ECIO 2025: Innovative Cryoablation for Breast Cancer Treatment

IceCure Medical Ltd. recently showcased its leading cryoablation technology, ProSense®, at the European Conference on Interventional Oncology 2025 (ECIO) in Rotterdam, Netherlands. Held from April 13 to April 16, 2025, the conference centered on advancements in cancer treatments, particularly focusing on the use of cryoablation for breast cancer.

With an impressive array of presentations and training sessions, ProSense® was a significant highlight at the event. Notably, two independent scientific sessions reported findings from various studies that utilized ProSense® in breast cancer treatment. Data shared from the THERMAC trial underlined the system's exceptional performance: 95% of participating patients indicated a preference for thermal ablation using ProSense® over traditional breast conserving surgery. This statistic reflects the growing acceptance and demand for minimally invasive cancer treatments in Europe.

Dr. Sophie Wooldrik, a leading breast surgeon, presented her findings on thermal ablation techniques, reiterating the advantages of cryoablation. Her conclusion emphasized that only cryoablation met the necessary criteria to advance to phase 3 studies, achieving a remarkable efficacy rate of 94% and a 0% complication rate.

Parallel insights were shared by Professor Thomas J. Vogl from Germany, who assessed the efficacy and safety of CT-guided cryoablation for primary breast cancer in his own presentation. His research involved 45 patients with a mean overall progression-free survival of 2.9 years, reinforcing the prospect of cryoablation as a safe and effective method for managing breast cancer.

The conference also included an insightful poster presentation that deep-dived into non-surgical treatments for patients unable to undergo surgery. This particular research illuminated that combining cryoablation with hormonal therapy yielded better outcomes in tumor size reductions when compared to using either treatment alone. Out of 64 patients who weren't suitable for surgical intervention, the results showcased a promising 94% reduction in tumor size with the combined therapy of cryoablation and hormones.

Alongside these thought-provoking presentations, IceCure facilitated three hands-on training sessions spotlighting the ProSense® system. These sessions were met with enthusiasm, showcasing the device's user-friendly design and effective functionality. The training aimed to educate medical professionals, arming them with practical knowledge that could lead to wider adoption of the technology in their respective practices.

As Eyal Shamir, CEO of IceCure Medical, conveyed: “As minimally invasive technologies like ProSense® advance the science of cancer care, interventional oncology is becoming a preferred pathway for the treatment of breast cancer in Europe. We believe that ProSense® stands out as the leading cryoablation system for early-stage breast cancer tumors currently available.”

The significance of these presentations and the collaborations formed during the event signify a bright future for ProSense® and further development in the realm of cryoablation technology. IceCure's dedication to refining surgical methods and improving patient outcomes through innovative treatments is reflected not just in the achievements of ProSense®, but also in the broader dialogue surrounding minimally invasive therapeutic options for cancer care.

About ProSense®

The ProSense® Cryoablation System epitomizes a groundbreaking advancement in the field of oncology. Its design allows for the precise freezing of tumors, using liquid nitrogen to enhance the destruction of both benign and malignant lesions. This method is not only tailored for breast tumors, but also extends its efficacy to kidney, lung, and liver cancers.

By improving patient recovery times and minimizing complications, ProSense® is reshaping the standard of care for oncology treatments. Its portability promotes quick implementation in various medical settings, which is vital in today’s fast-paced healthcare environment. IceCure Medical continues to lead the way in developing this cutting-edge cryoablation technology, aiming for broader global accessibility and enhanced treatment options for patients across numerous cancer types.

In conclusion, the enriching experience and knowledge sharing at ECIO 2025 underscore the emerging potential of cryoablation as a preferred treatment pathway, emphasizing ProSense® role in pioneering this change.